湯寧信
教授(內科及臨床藥理學)
所在部門 醫學院(FMD)
辦公室 擎天匯校區 PP-R211c
電子信箱 btomlinson@must.edu.mo
Brian Tomlinson graduated with MBBS from the Middlesex Hospital Medical School, University of London, and specialized in Clinical Pharmacology and Clinical Toxicology and completed his MD at University College Hospital, London. He joined The Chinese University of Hong Kong as Senior Lecturer and later was appointed as Head of the Division of Clinical Pharmacology and subsequently Professor of Medicine and Therapeutics at CUHK. He joined Macau University of Science and Technology as Professor in the Faculty of Medicine and as Consultant Physician at the University Hospital in 2019. His specialist clinical and research interests focus on the causes and treatment of hyperlipidaemia, hypertension, the metabolic syndrome and diabetes. He has been awarded numerous grants for research and has been an investigator in many clinical trials including Phase 1 Clinical Trials and later Phase trials in hyperlipidaemia, hypertension and diabetes.
學歷

BSc (London), 1970 MBBS (London), 1973 MRCP (UK), 1976 MD (London), 1993

教學領域

Internal medicine, Basic and Clinical Pharmacology, Clinical Toxicology

研究領域

Causes and treatment of hyperlipidaemia, hypertension, metabolic syndrome and diabetes.

工作經歷

1980-1983, Lecturer in Medicine, University College Hospital, London, UK, 1983-1990, Lecturer in Clinical Pharmacology & Honorary Senior Registrar, University College and Middlesex School of Medicine, University College London, U.K. 1990-2015, Senior Lecturer then Professor of Medicine and Therapeutics, Head of Division of Clinical Pharmacology, The Chinese University of Hong Kong, Hong Kong 1990-2015, Honorary Consultant Physician, Prince of Wales Hospital, Shatin, Hong Kong 2015-present, Clinical Professor (Honorary) Department of Medicine & Therapeutics, The Chinese University of Hong Kong 2015-present, Consultant, Phase I Clinical Trial Centre, The Chinese University of Hong Kong 2019-present, Professor, Faculty of Medicine, Macau University of Science and Technology, Macau, China.

學術出版物(精選)

Selected recent publications from over 500 in peer-reviewed, indexed journals. 1.        Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction. Yeh JS, Chen WT, Tomlinson B, Tam WC and Chien LN. Front Cardiovasc Med. 2023;10:1143509. 2.        Endothelial Gata6 deletion reduces monocyte recruitment and proinflammatory macrophage formation and attenuates atherosclerosis through Cmpk2-Nlrp3 pathways. Wu W, Bao W, Chen X, Lu Y, Fang J, Liu J, Peng S, Pi J, Tomlinson B, Chan P, Zhang Q, Zhang L, Liu Z, Liu J, Zhang Y and Zhuang T. Redox Biol. 2023;64:102775. 3.        The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients. Wang X, Chen X, Wang Y, Peng S, Pi J, Yue J, Meng Q, Liu J, Zheng L, Chan P, Tomlinson B, Liu Z and Zhang Y. Int J Gen Med. 2023;16:2805-2817. 4.        Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date. Tomlinson B and Li YH. Expert Opin Pharmacother. 2023;24:1937-1947. 5.        What is the impact of type 2 diabetes mellitus on CYP450 metabolic activities? Tomlinson B and Li YH. Expert Opin Drug Metab Toxicol. 2023:1-4. 6.        Identification of a Common Variant for Coronary Heart Disease at PDE1A Contributes to Individualized Treatment Goals and Risk Stratification of Cardiovascular Complications in Chinese Patients With Type 2 Diabetes. Tam CHT,…..Tomlinson B, …..Ma RCW, Hong Kong Diabetes Biobank Study Group FSI, Complications TRAo and Consortium ENiD. Diabetes Care. 2023;46:1271-1281. 7.        Molecular mechanisms and therapeutic perspectives of peroxisome proliferator-activated receptor alpha agonists in cardiovascular health and disease. Pu Y, Cheng CK, Zhang H, Luo JY, Wang L, Tomlinson B and Huang Y. Med Res Rev. 2023;43:2086-2114. 8.        Case report: Distinctive cardiac features and phenotypic characteristics of Noonan syndrome with multiple lentigines among three generations in one family. Chan CH, Chu MF, Lam UP, Mok TM, Tam WC, Tomlinson B, Coelho R and Evora M. Front Cardiovasc Med. 2023;10:1225667. 9.        Suzuki K, ………Tomlinson B, ……….., Morris AP, Zeggini E. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature. 2024. doi: 10.1038/s41586-024-07019-6. 10.        Jin Q, ……, Tomlinson B, ……, Ma RCW, Hong Kong Diabetes Biobank Study G. Circulating metabolomic markers linking diabetic kidney disease and incident cardiovascular disease in type 2 diabetes: analyses from the Hong Kong Diabetes Biobank. Diabetologia. 2024. doi: 10.1007/s00125-024-06108-5.

書籍

Ancient and Traditional Foods, Plants, Herbs and Spices used in Cardiovascular Health and Disease. V. CRC Press R. P. Rajkumar Rajendram, Vinood B. Patel, ed., Lingzhi (Ganoderma lucidum) and Cardiovascular Disease. 2023:247-257. Tomlinson B, Chan SW and Chan P. Ancient and Traditional Foods, Plants, Herbs and Spices used in Diabetes: CRC Press V. R. P. Rajkumar Rajendram, Vinood B. Patel, ed., Beneficial Effects of Bilberry (Vaccinium myrtillus L.) in Diabetes and Cardiovascular Disease, 2023: 139-150. Chan S and Tomlinson B.

專利
專業認證和獎項

1992, Fellow of the Hong Kong College of Physicians, FHKCP         1994, Fellow of the Royal College of Physicians of London, FRCP(Lond)         1994, Fellow of the Royal College of Physicians of Edinburgh, FRCP(Edin)         1994, Fellow of the Hong Kong Academy of Medicine (Medicine), FHKAM(Medicine)         1996, Fellow of the American College of Clinical Pharmacology, FCP         1997, Fellow of the American College of Physicians, FACP         1997, Fellow of the Hong Kong College of Cardiology         2000, Fellow of the Royal College of Physicians and Surgeons of Glasgow, FRCP(Glasg)

專業協會會員資格

1. Chair of Asia-Pacific Regional Federation of the International Atherosclerosis Society (IAS) from 2019. 2. Former President of the Asian-Pacific Society of Atherosclerosis & Vascular Diseases 3. President of Hong Kong Pharmacological Society from 2018 4. Member of the International Society of Hypertension 5. Member of the Hong Kong Medical Association 6. Member of the British Medical Association (Hong Kong Branch, former Vice President)